Bristol-Myers Squibb-backed Zenas BioPharma files for
US IPO causing the company's stock to rise, though it's still underperforming the market.
FDAs are discussing limiting the use of Cancer drugs from Merck, Bristol-Myers, and BeiGene. There are worries over job cuts in New Jersey with Bristol Myers hinting at eliminating 117 jobs.
Earnings reports have reinforced many analysts' thesis about the company's strong performance. The company received U.S Food and Drug Administration
sBLA acceptance for First-Line treatment of unresectable hepatocellular carcinoma. Bristol Myers is facing various challenges such as Abecma competition, Sotyktu pricing pressure, and IRA. The company was hit by FDA over misleading Krazati efficacy claims. Bristol Myers to pay $2.7 million to settle Israel anti-competition charges. Expect a decrease in earnings according to analysts' estimates. A newly formed partnership with Repertoire worth $1.8 billion aims to develop
vaccines for autoimmune diseases. The company plans to cut 6% of its workforce and trim its drug pipeline while launching a $1.5 billion cost-saving plan. It expands health equity grant initiatives to improve health outcomes.
Bristol-Myers Squibb News Analytics from Wed, 20 Dec 2023 08:00:00 GMT to Sun, 25 Aug 2024 13:54:13 GMT -
Rating 7
- Innovation 3
- Information 6
- Rumor 3
